SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.
The SELECT-MDS-1 trial showed no significant complete response rate improvement with tamibarotene plus azacitidine for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback